Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Merger/License Dance of AstraZeneca, Forest and Novexel

This article was originally published in Start Up

Executive Summary

As public health officials warn about new strains of resistant bacteria spreading in hospitals, drug firms have been slow to produce new ammunition. But the past few years have seen a spate of deals, both licenses and acquisitions, among firms maneuvering into the antibiotic space. The latest antibiotic deal-AstraZeneca PLC's two-step, $350 million acquisition of Novexel SA--happened just before the winter holidays and was easy to overlook amid the year-end flurry of industry action. It's worth revisiting for a few reasons.

You may also be interested in...



AZ Spins Out Entasis To Tackle Resistant Infections

AstraZeneca has, after a long gestation, given birth to the antibiotic developer Entasis Therapeutics: in early July the biotech debuted with $40 million in funding from AZ alone, and a portfolio of the drugmaker’s early-stage antibiotic candidates. It emerges as the debate about incentivizing antibiotics R&D intensifies amid growing concerns about antibiotic-resistant bacteria.

At PSA, Meet The New Deal-Makers (Part 2)

At EBI's Pharmaceutical Strategic Alliances conference in New York on Sept. 22, BD experts addressed key issues for their profession as pharma revamps the way it balances internal and external R&D.

At PSA, Meet The New Deal-Makers (Part 2)

At EBI's Pharmaceutical Strategic Alliances conference in New York on Sept. 22, BD experts addressed key issues for their profession as pharma revamps the way it balances internal and external R&D.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091887

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel